Euglycaemic diabetic ketoacidosis as a complication of SGLT-2 inhibitors: epidemiology, pathophysiology, and treatment-Reference-Cited by-同舟云学术

Euglycaemic diabetic ketoacidosis as a complication of SGLT-2 inhibitors: epidemiology, pathophysiology, and treatment

Published:2020-06-02 Issue:6 Volume:19 Page:673-682
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Sampani Erasmia¹,Sarafidis Pantelis¹,Papagianni Aikaterini¹

Affiliation:

1. Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2020.1764532

Reference75 articles.

1. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040

2. Ketoacidosis occurs in both Type1 and Type2 diabetes a population-based study from Northern Sweden

3. FDA Drug Safety. Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. [cited 2019 Dec 17]. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm475463.htm

4. Hyperglycemic Crises in Adult Patients With Diabetes

5. U.S. Food and Drug Administration 2015. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. [cited 2019 Dec 17]. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM446954.pdf

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dapagliflozin: A new hope for the therapeutic treatment of type 2 diabetes mellitus;European Journal of Medicinal Chemistry Reports;2024-08

2. Management of Diabetes Mellitus in Acromegaly and Cushing’s Disease with Focus on Pasireotide Therapy: A Narrative Review;Diabetes, Metabolic Syndrome and Obesity;2024-07

3. Ketoacidosis and SGLT2 Inhibitors: A Narrative Review;Metabolites;2024-05-06

4. Empagliflozin-associated postoperative mixed metabolic acidosis. Case report and review of pathogenesis;2022-12-07

5. Sodium‐glucose cotransporter‐2 inhibitor‐induced euglycemic diabetic ketoacidosis: A case report;Journal of Clinical Pharmacy and Therapeutics;2022-08-10